{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T15:57:02Z","timestamp":1762271822666},"reference-count":45,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2014,8,22]],"date-time":"2014-08-22T00:00:00Z","timestamp":1408665600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0105526","type":"journal-article","created":{"date-parts":[[2014,8,22]],"date-time":"2014-08-22T19:25:09Z","timestamp":1408735509000},"page":"e105526","update-policy":"http:\/\/dx.doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":9,"title":["Inhibition of c-Abl Kinase Activity Renders Cancer Cells Highly Sensitive to Mitoxantrone"],"prefix":"10.1371","volume":"9","author":[{"given":"Kemal","family":"Alpay","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehdi","family":"Farshchian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johanna","family":"Tuomela","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jouko","family":"Sandholm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaappo","family":"Aittokallio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elina","family":"Siljam\u00e4ki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marko","family":"Kallio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veli-Matti","family":"K\u00e4h\u00e4ri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sakari","family":"Hietanen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2014,8,22]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1038\/21697","article-title":"Interaction of c-Abl and p73alpha and their collaboration to induce apoptosis","volume":"399","author":"R Agami","year":"1999","journal-title":"Nature"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.mad.2007.05.002","article-title":"Genome maintenance mechanisms are critical for preventing cancer as well as other aging-associated diseases","volume":"128","author":"JH Hoeijmakers","year":"2007","journal-title":"Mech Ageing Dev"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.bcp.2011.07.001","article-title":"DNA damage response: the emerging role of c-Abl as a regulatory switch","volume":"82","author":"E Maiani","year":"2011","journal-title":"Biochem Pharmacol"},{"key":"ref4","first-page":"re6","article-title":"ABL tyrosine kinases: evolution of function, regulation, and specificity","volume":"139","author":"J Colicelli","year":"2010","journal-title":"SciSignal"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/ncb0104-3","article-title":"Controlling Abl: auto-inhibition and co-inhibition","volume":"6","author":"JY Wang","year":"2004","journal-title":"Nat Cell Biol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1518S","DOI":"10.1093\/jn\/137.6.1518S","article-title":"c-Abl tyrosine kinase and inhibition by the cancer drug imatinib (Gleevec\/STI-571)","volume":"137","author":"B Nagar","year":"2007","journal-title":"J Nutr"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/S1097-2765(01)00357-4","article-title":"BCR\/ABL regulates mammalian RecA homologs, resulting in drug resistance","volume":"8","author":"A Slupianek","year":"2001","journal-title":"Mol Cell"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1016\/S0959-8049(02)80600-1","article-title":"Pharmacology of imatinib (STI571)","volume":"38","author":"E Buchdunger","year":"2002","journal-title":"Eur J Cancer"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/cdd.2010.106","article-title":"A positive role for c-Abl in Atm and Atr activation in DNA damage response","volume":"18","author":"X Wang","year":"2011","journal-title":"Cell Death Differ"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"12748","DOI":"10.1074\/jbc.274.18.12748","article-title":"Radiation-induced assembly of Rad51 and Rad52 recombination complex requires ATM and c-Abl","volume":"274","author":"G Chen","year":"1999","journal-title":"J Biol Chem"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1002\/pros.20201","article-title":"In vitro cytotoxic effects of imatinib in combination with anticancer drugs in human prostate cancer cell lines","volume":"63","author":"HR Kubler","year":"2005","journal-title":"Prostate"},{"key":"ref12","first-page":"7377","article-title":"Gleevec-mediated inhibition of Rad51 expression and enhancement of tumor cell radiosensitivity","volume":"63","author":"JS Russell","year":"2003","journal-title":"Cancer Res"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1158\/1535-7163.MCT-08-0959","article-title":"Targeting homologous recombination using imatinib results in enhanced tumor cell chemosensitivity and radiosensitivity","volume":"8","author":"A Choudhury","year":"2009","journal-title":"Mol Cancer Ther"},{"key":"ref14","first-page":"O1","article-title":"Functional role for the c-Abl protein tyrosine kinase in the cellular response to genotoxic stress","volume":"1333","author":"S Kharbanda","year":"1997","journal-title":"Biochim Biophys Acta"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/nrc798","article-title":"Papillomaviruses and cancer: from basic studies to clinical application","volume":"2","author":"H zur Hausen","year":"2002","journal-title":"Nat Rev Cancer"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Hietanen S (2009) Apoptosis in Carcinogenesis and Chemoherapy of the Uterine Cervix. In: Chen GG, Lai PBS, editors. Apoptosis in Carcinogenesis and Chemotherapy: Springer Netherlands. pp.51\u201373.","DOI":"10.1007\/978-1-4020-9597-9_3"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.4161\/cbt.3.11.1340","article-title":"The cytotoxicity of chemotherapy drugs varies in cervical cancer cells depending on the p53 status","volume":"3","author":"R Koivusalo","year":"2004","journal-title":"Cancer Biol Ther"},{"key":"ref18","first-page":"7364","article-title":"Chemoradiation of cervical cancer cells: targeting human papillomavirus E6 and p53 leads to either augmented or attenuated apoptosis depending on the platinum carrier ligand","volume":"62","author":"R Koivusalo","year":"2002","journal-title":"Cancer Res"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1002\/(SICI)1097-0215(19981029)78:3<338::AID-IJC14>3.0.CO;2-2","article-title":"Anti-proliferative effect of retinoids and interferon-alpha-2a on vaginal cell lines derived from squamous intra-epithelial lesions","volume":"78","author":"S Hietanen","year":"1998","journal-title":"Int J Cancer"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1124\/mol.105.011189","article-title":"Chemotherapy compounds in cervical cancer cells primed by reconstitution of p53 function after short interfering RNA-mediated degradation of human papillomavirus 18 E6 mRNA: opposite effect of siRNA in combination with different drugs","volume":"68","author":"R Koivusalo","year":"2005","journal-title":"Mol Pharmacol"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1097\/01.mlg.0000225895.40732.52","article-title":"STI-571 (Gleevec) potentiates the effect of cisplatin in inhibiting the proliferation of head and neck squamous cell carcinoma in vitro","volume":"116","author":"J Wang-Rodriguez","year":"2006","journal-title":"Laryngoscope"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.mrfmmm.2004.11.018","article-title":"The cell cycle phases of DNA damage and repair initiated by topoisomerase II-targeting chemotherapeutic drugs","volume":"572","author":"AJ Potter","year":"2005","journal-title":"Mutat Res"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"4385","DOI":"10.1038\/onc.2008.86","article-title":"Activated c-Abl tyrosine kinase in malignant solid tumors","volume":"27","author":"J Lin","year":"2008","journal-title":"Oncogene"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/1423-0127-19-35","article-title":"STI571 reduces TRAIL-induced apoptosis in colon cancer cells: c-Abl activation by the death receptor leads to stress kinase-dependent cell death","volume":"19","author":"DY Huang","year":"2012","journal-title":"J Biomed Sci"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s00280-010-1315-z","article-title":"Schedule treatment design and quantitative in vitro evaluation of chemotherapeutic combinations for metastatic prostate cancer therapy","volume":"67","author":"AC Pinto","year":"2011","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1002\/pros.21224","article-title":"Liposomal imatinib-mitoxantrone combination: formulation development and therapeutic evaluation in an animal model of prostate cancer","volume":"71","author":"AC Pinto","year":"2011","journal-title":"Prostate"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.uct.2008.02.001","article-title":"Topoisomerase II inhibitors","volume":"3","author":"KR Hande","year":"2008","journal-title":"Update Cancer Ther"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.bcp.2009.04.002","article-title":"Nilotinib (AMN107, Tasigna) reverses multidrug resistance by inhibiting the activity of the ABCB1\/Pgp and ABCG2\/BCRP\/MXR transporters","volume":"78","author":"AK Tiwari","year":"2009","journal-title":"Biochem Pharmacol"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1158\/0008-5472.CAN-03-3344","article-title":"Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro","volume":"64","author":"PJ Houghton","year":"2004","journal-title":"Cancer Res"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1124\/mol.105.017988","article-title":"Multidrug resistance protein 1 (MRP1, ABCC1) mediates resistance to mitoxantrone via glutathione-dependent drug efflux","volume":"69","author":"CS Morrow","year":"2006","journal-title":"Mol Pharmacol"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"e55509","DOI":"10.1371\/journal.pone.0055509","article-title":"Imatinib reverses doxorubicin resistance by affecting activation of STAT3-dependent NF-kappaB and HSP27\/p38\/AKT pathways and by inhibiting ABCB1","volume":"8","author":"JT Sims","year":"2013","journal-title":"PLoS One"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"e37735","DOI":"10.1371\/journal.pone.0037735","article-title":"Nilotinib counteracts P-glycoprotein-mediated multidrug resistance and synergizes the antitumoral effect of doxorubicin in soft tissue sarcomas","volume":"7","author":"VH Villar","year":"2012","journal-title":"PLoS One"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1038\/sj.onc.1210714","article-title":"Aggressive breast cancer cells are dependent on activated Abl kinases for proliferation, anchorage-independent growth and survival","volume":"27","author":"D Srinivasan","year":"2008","journal-title":"Oncogene"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"2400","DOI":"10.1101\/gad.13.18.2400","article-title":"c-Abl is activated by growth factors and Src family kinases and has a role in the cellular response to PDGF","volume":"13","author":"R Plattner","year":"1999","journal-title":"Genes Dev"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1093\/emboj\/21.4.514","article-title":"c-Abl is an effector of Src for growth factor-induced c-myc expression and DNA synthesis","volume":"21","author":"O Furstoss","year":"2002","journal-title":"EMBO J"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"3554","DOI":"10.1098\/rstb.2011.0071","article-title":"Surviving chromosome replication: the many roles of the S-phase checkpoint pathway","volume":"366","author":"K Labib","year":"2011","journal-title":"PhilosTrans R Soc Lond B Biol Sci"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"8501","DOI":"10.1073\/pnas.97.15.8501","article-title":"Activation of p53 in cervical carcinoma cells by small molecules","volume":"97","author":"S Hietanen","year":"2000","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1021\/bi301710c","article-title":"c-Abl phosphorylates E6AP and regulates its E3 ubiquitin ligase activity","volume":"52","author":"AL Chan","year":"2013","journal-title":"Biochemistry"},{"key":"ref39","volume":"399","unstructured":"White E, Prives C (1999) DNA damage enables p73. Nature <volume>399<\/volume>: : 734\u2013735, 737."},{"key":"ref40","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1038\/21704","article-title":"p73 is regulated by tyrosine kinase c-Abl in the apoptotic response to DNA damage","volume":"399","author":"ZM Yuan","year":"1999","journal-title":"Nature"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1038\/nm.2033","article-title":"Inhibition of the c-Abl-TAp63 pathway protects mouse oocytes from chemotherapy-induced death","volume":"15","author":"S Gonfloni","year":"2009","journal-title":"Nat Med"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1038\/nm.2889","article-title":"Cisplatin-induced primordial follicle oocyte killing and loss of fertility are not prevented by imatinib","volume":"18","author":"JB Kerr","year":"2012","journal-title":"Nat Med"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.1038\/cddis.2009.21","article-title":"c-Abl downregulates the slow phase of double-strand break repair","volume":"1","author":"V Meltser","year":"2010","journal-title":"Cell Death Dis"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"4380","DOI":"10.1038\/onc.2008.68","article-title":"Pharmacological inhibition of c-Abl compromises genetic stability and DNA repair in Bcr-Abl-negative cells","volume":"27","author":"S Fanta","year":"2008","journal-title":"Oncogene"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.molcel.2006.04.021","article-title":"A kinase-independent function of c-Abl in promoting proteolytic destruction of damaged DNA binding proteins","volume":"22","author":"X Chen","year":"2006","journal-title":"Mol Cell"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0105526","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,23]],"date-time":"2020-08-23T16:26:03Z","timestamp":1598199963000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0105526"}},"subtitle":[],"editor":[{"given":"Stephan Neil","family":"Witt","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2014,8,22]]},"references-count":45,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2014,8,22]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0105526","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,8,22]]}}}